Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.34 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7706083 | 1.00 | CCR2 (0.34) | CCR2PLGAR | |
| SCHEMBL24963541 | 0.88 | CCR2 (0.39) | CCR2 | |
| SCHEMBL24188796 | 0.86 | CCR2 (0.45) | CCR2 | |
| SCHEMBL24189428 | 0.82 | CCR2 (0.38) | CCR2AR | |
| SCHEMBL25766118 | 0.82 | CCR2 (0.38) | CCR2AR | |
| SCHEMBL21164841 | 0.80 | PLG (0.35) | CCR2PLGAR | |
| SCHEMBL25766120 | 0.80 | CCR2 (0.40) | CCR2AR | |
| SCHEMBL12070429 | 0.80 | CCR2 (0.33) | CCR2AR | |
| SCHEMBL12070430 | 0.80 | CCR2 (0.33) | CCR2AR | |
| SCHEMBL30497365 | 0.79 | AR (0.34) | AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-6610730-B2 | Viricides; protease inbhibitor | AGOURON PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6610730-B2 | Viricides; protease inbhibitor | AGOURON PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6534530-B1 | Administering (benzo)thiazole peptidomimetic as viricide; protease inhibitors | AGOURON PHARMACEUTICALS, INC. | 2003-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10988478-B1 | Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK1, IRAK4, IRAK2 | CCR2 784/4885PLG 3844/4885AR 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.